Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Rigetti has technical credibility and a proposed $100M federal quantum award, but the investment case still hinges on revenue scale, cash burn, fidelity, and system roadmap execution.
OpenA Coverage Bootstrap TSMC company evaluation covering advanced-node foundry leadership, CoWoS, customers, margins, capex, global fabs, Taiwan risk, and valuation setup.
OpenD-Wave has one of the clearest customer-demand signals in quantum after record bookings, but the Q1 revenue base remained small and losses expanded.
OpenA Coverage Bootstrap NVIDIA company evaluation covering AI accelerators, CUDA, networking, data-center concentration, margins, export controls, valuation risk, and proof gates.
OpenA refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenA Coverage Bootstrap Microsoft company evaluation covering Azure, Microsoft 365, Copilot, AI capex, enterprise distribution, security, gaming, regulation, and valuation setup.
OpenInfleqtion has a clean quantum identity, record Q1 revenue, and a proposed $100M federal tailwind, but the business still needs revenue scale and operating-loss discipline.
OpenGlobalFoundries has the largest public-market quantum foundry angle in this batch, but investors still need proof that the proposed CHIPS funding and customer engagements become durable demand instead of a one-day headline.
OpenA Coverage Bootstrap Datavault AI company evaluation covering data monetization, credentialing, ADIO, RWA tokenization, exchange infrastructure, customer concentration, related-party revenue, dilution, and cash-conversion proof.
OpenA Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
OpenA Coverage Bootstrap Constellation Energy company evaluation covering nuclear fleet economics, clean firm power, data-center PPAs, regulation, fleet reliability, acquisitions, and valuation risk.
OpenA Coverage Bootstrap Bloom Energy company evaluation covering fuel cells, data-center power demand, revenue growth, adjusted EBITDA, margins, project execution, cash flow, and risk controls.
OpenBigBear.ai's Q1 2026 backlog and gross margin improved, but the deep dive keeps the proof gate on revenue conversion, adjusted EBITDA, and operating cash flow.
OpenA Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenA Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
OpenA filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenZymeworks Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZhengye Biotechnology Holding Limited has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZurn Elkay Water Solutions Corporation has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenZevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Open